MC2308A1 - Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine - Google Patents
Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaineInfo
- Publication number
- MC2308A1 MC2308A1 MC912308D MC2308D MC2308A1 MC 2308 A1 MC2308 A1 MC 2308A1 MC 912308 D MC912308 D MC 912308D MC 2308 D MC2308 D MC 2308D MC 2308 A1 MC2308 A1 MC 2308A1
- Authority
- MC
- Monaco
- Prior art keywords
- peptides
- immunodeficiency virus
- human immunodeficiency
- against human
- vaccination
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 101900082162 Human immunodeficiency virus type 1 group M subtype B Surface protein gp120 Proteins 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58942290A | 1990-09-27 | 1990-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MC2308A1 true MC2308A1 (fr) | 1993-09-27 |
Family
ID=24357953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MC912308D MC2308A1 (fr) | 1990-09-27 | 1991-09-27 | Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine |
Country Status (13)
Country | Link |
---|---|
US (1) | US5589175A (de) |
EP (1) | EP0550599B1 (de) |
JP (1) | JPH06501260A (de) |
AT (1) | ATE238065T1 (de) |
AU (1) | AU650911B2 (de) |
CA (1) | CA2091263C (de) |
DE (1) | DE69133242T2 (de) |
ES (1) | ES2194836T3 (de) |
FI (1) | FI931393A (de) |
HU (1) | HU9300877D0 (de) |
MC (1) | MC2308A1 (de) |
OA (1) | OA09802A (de) |
WO (1) | WO1992005800A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5939074A (en) * | 1986-12-30 | 1999-08-17 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptide antigens |
US5346989A (en) * | 1990-08-22 | 1994-09-13 | Syntello Vaccine Development Kb | Peptides for use in induction of T cell activation against HIV-1 |
WO1992021377A1 (en) * | 1991-06-03 | 1992-12-10 | Syntello Inc. | Peptides for use in induction of t cell activation against hiv-1 |
DK0601108T3 (da) * | 1991-08-29 | 2000-04-17 | Us Gov Health & Human Serv | Multideterminante peptidantigener, som stimulerer T-hjælpelymfocytrespons til HIV hos en gruppe mennesker |
IT1254360B (it) * | 1992-05-11 | 1995-09-14 | San Romanello Centro Fond | Epitopi immunologicamente omologhi di hla e proteine del virus hiv. |
DE4228787A1 (de) * | 1992-08-29 | 1994-03-03 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Neue HIV-1-Virusisolate eines Subtyps, Vakzine gegen HIV-1-Virusinfektionen dieses Subtyps und Verfahren zu ihrer Herstellung, Verwendung der HIV-1-Virusisolate |
WO1994023746A1 (en) * | 1993-04-16 | 1994-10-27 | Syntello Vaccine Development Ab | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
FR2707170A1 (fr) * | 1993-06-04 | 1995-01-13 | Pasteur Institut | Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26. |
FR2707169B1 (fr) * | 1993-06-04 | 1995-09-01 | Pasteur Institut | Antigène cellulaire CD26 impliqué dans l'infection par un rétrovirus hiv. nouveaux inhibiteurs de l'infection par HIV. * (Dipeptidyl-peptidase IV). |
DE4405810A1 (de) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
AU2991197A (en) * | 1996-04-15 | 1997-11-07 | University Of North Carolina At Chapel Hill, The | Antigenic sequences of a sperm protein and immunocontraceptive methods |
US7048929B1 (en) * | 1997-11-10 | 2006-05-23 | Dana-Farber Cancer Institute, Inc. | Stabilized primate lentivirus envelope glycoproteins |
WO2008017517A1 (en) | 2006-08-11 | 2008-02-14 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in immune disorders |
US8999346B2 (en) | 2008-02-14 | 2015-04-07 | Life Sciences Research Partners Vzw | Immunogenic control of tumours and tumour cells |
EP2719396B1 (de) | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Auf intrazelluläre Pathogene abzielende Immuntherapie |
RU2615460C2 (ru) * | 2010-11-25 | 2017-04-04 | Имнейт Сарл | Иммуногенные пептиды для применения в профилактике и/или лечении инфекционных заболеваний, аутоиммунных заболеваний, иммунных ответов на аллогенные факторы, аллергических заболеваний, опухолей, отторжения трансплантата и иммунных ответов против вирусных векторов. используемых для генной терапии или генной вакцинации |
GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
WO2017050966A1 (en) | 2015-09-25 | 2017-03-30 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
US11485768B2 (en) | 2016-04-19 | 2022-11-01 | Imcyse Sa | Immunogenic CD1d binding peptides |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3587181T2 (de) * | 1984-10-18 | 1993-06-24 | Centre Nat Rech Scient | F antigene vom menschlichen immunodefizienz-virus und deren verwendungen. |
AU617088B2 (en) * | 1986-06-12 | 1991-11-21 | Biogen, Inc. | Peptides involved in the pathogenesis of hiv infection |
US5128319A (en) * | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
US5019387A (en) * | 1987-09-08 | 1991-05-28 | Duke University | Production of antibodies to HIV |
WO1989005820A1 (en) * | 1987-12-21 | 1989-06-29 | Arch Development Corporation | Hiv-related antigens and antibodies |
EP0330359A3 (de) * | 1988-02-25 | 1991-06-05 | Bio-Rad Laboratories, Inc. | Zusammensetzung, verwendbar zur Diagnose und Behandlung von HIV-I-Infektion |
WO1989010416A1 (en) * | 1988-04-20 | 1989-11-02 | Trustees Of The University Of Pennsylvania | PROTECTIVE PEPTIDES DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUS-1 gp160 |
US4943628A (en) * | 1988-06-13 | 1990-07-24 | Ortho Pharmaceutical Corporation | HIV peptide-inducted T cell stimulation |
AU7676891A (en) * | 1990-04-03 | 1991-10-30 | Genentech Inc. | Hiv envelope polypeptides |
AP237A (en) * | 1990-05-29 | 1993-04-29 | Cedars Sinai Medical Center | Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use. |
WO1992021377A1 (en) * | 1991-06-03 | 1992-12-10 | Syntello Inc. | Peptides for use in induction of t cell activation against hiv-1 |
-
1991
- 1991-09-25 JP JP3516126A patent/JPH06501260A/ja active Pending
- 1991-09-25 AU AU86435/91A patent/AU650911B2/en not_active Ceased
- 1991-09-25 ES ES91917502T patent/ES2194836T3/es not_active Expired - Lifetime
- 1991-09-25 AT AT91917502T patent/ATE238065T1/de not_active IP Right Cessation
- 1991-09-25 DE DE69133242T patent/DE69133242T2/de not_active Expired - Fee Related
- 1991-09-25 CA CA002091263A patent/CA2091263C/en not_active Expired - Fee Related
- 1991-09-25 WO PCT/SE1991/000641 patent/WO1992005800A1/en active IP Right Grant
- 1991-09-25 HU HU93877A patent/HU9300877D0/hu unknown
- 1991-09-25 EP EP91917502A patent/EP0550599B1/de not_active Expired - Lifetime
- 1991-09-27 MC MC912308D patent/MC2308A1/xx unknown
-
1993
- 1993-03-23 OA OA60353A patent/OA09802A/en unknown
- 1993-03-26 FI FI931393A patent/FI931393A/fi not_active Application Discontinuation
-
1995
- 1995-03-27 US US08/410,384 patent/US5589175A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69133242T2 (de) | 2004-02-19 |
ES2194836T3 (es) | 2003-12-01 |
EP0550599B1 (de) | 2003-04-23 |
AU650911B2 (en) | 1994-07-07 |
WO1992005800A1 (en) | 1992-04-16 |
AU8643591A (en) | 1992-04-28 |
CA2091263C (en) | 2003-05-06 |
DE69133242D1 (de) | 2003-05-28 |
OA09802A (en) | 1994-04-15 |
JPH06501260A (ja) | 1994-02-10 |
EP0550599A1 (de) | 1993-07-14 |
FI931393A0 (fi) | 1993-03-26 |
FI931393A (fi) | 1993-03-26 |
US5589175A (en) | 1996-12-31 |
CA2091263A1 (en) | 1992-03-28 |
ATE238065T1 (de) | 2003-05-15 |
HU9300877D0 (en) | 1993-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MC2308A1 (fr) | Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine | |
FR12C0004I2 (fr) | Anticorps contre l'antigene ctla-4 humain et utilisation | |
BR9814487A (pt) | "vacina" | |
ATE364621T1 (de) | Hiv-peptide | |
ES2013328A6 (es) | Un metodo para detectar anticuerpos contra antigenos hiv-1. | |
ATE305971T1 (de) | Monoklonale antikörper und fv gegen das cd2 antigen | |
TR199801722T2 (xx) | Peptit imm�nojenler. | |
FR2603107A1 (fr) | Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus | |
ATE135743T1 (de) | Monoklonale menschliche antikörper gegen hiv-i | |
FR2610631B1 (fr) | Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme | |
NZ296564A (en) | Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides | |
ATE206620T1 (de) | Menschliche, monoklonale antikörper gegen das transmembrane glycoprotein (gp41) des hiv-1, und verwandte peptide | |
DE69330352D1 (de) | Mittel und methoden zur verbesserung der keratinocytenadhäsion an der haut | |
SE9000333D0 (sv) | Monoklonal antikropp | |
ATE285418T1 (de) | Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation | |
ATE435034T1 (de) | Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist. | |
RU94046321A (ru) | Моноклональные муриновые антиидиотипические антитела, способ их получения и их применение, способы иммунизации и фармацевтический состав на их основе | |
HUP0003511A2 (hu) | Hepatitisz-B-vírus polipeptidek | |
ATE247485T1 (de) | Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus | |
ATE134649T1 (de) | Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern | |
DK0426314T3 (da) | HIV-relaterede peptider | |
RU93004854A (ru) | Пептиды для вакцинации и индукции нейтрализующих антител против вируса иммунодефицита человека | |
FR2646607B1 (fr) | Anticorps monoclonaux anti-b2 microglobuline | |
US20010007017A1 (en) | Peptides which react with antibody representing the prognostic marker for hiv disease progression | |
Vahlne et al. | Peptides for induction of neutralizing antibodies against human immunodeficiency virus |